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Artificial intelligence (AI) is the science of training a ma-chine or computer to perform human tasks. The term AI 
was first used in 1955, and AI has recently become increasingly 
popular (1). Advanced algorithms, sophisticated computers 
with large power and storage options, and increased data 
volumes, have contributed to the increase in interest in AI. 
AI applications can be used in many aspects of society, and 
are expanding into areas that were previously considered tasks 
for human experts.
AI applications are being developed and used within health-
care, and the question arises as to whether AI might gradually 
change medical practice. A key future problem within global 
healthcare is the immense predicted shortage of healthcare 
workers. The World Health Organization (WHO) has estimated 
a shortfall of almost 13 million healthcare worker worldwide 
by 2035 (2). Within the field of dermatology a lack of special-
ists is already evident in the UK, with only 650 dermatologists 
for a population of over 66 million (3, 4). Dermatologists often 
work under pressure, with long waiting times and insufficient 
time to spend with patients. New technology, and especially 
AI, might be useful in this field, as diagnosis in dermatology 
to a great extent depends on the visual recognition of patho-
logical structures.
We performed a systematic review to identify current appli-
cations of AI within dermatology. Current and future appli-
cations, benefits and harms are reported here, together with 
the safety of different applications.
Methods
The Cochrane Library, Cochrane Central Register of Controlled 
Trials (CENTRAL), MEDLINE, Embase, Science Citation Index 
Expanded were searched until May 2019 using the search 
terms “artificial intelligence” or “computer-assisted”, “com-
puter-aided” and/or “dermatology” or “dermoscopy”. Relevant 
articles were selected, including randomized controlled trials 
and review articles. The reference sections of relevant articles 
were also searched for relevant publications. 
Results
Relevant publications on applications of AI for diagnosis 
in dermatology were identified. The selected articles were 
primarily review articles, Cochrane Reviews, and larger pro-
spective studies (5–23). Furthermore, some expert and user 
opinions were selected (1). The vast majority of publications 
deal with the diagnosis of malignant melanoma. This is un-
derstandable as malignant melanoma contributes to 80% of 
skin-cancer-related deaths (17). The annual incidence of ma-
lignant melanoma has increased dramatically in the last few 
decades, and the risk of melanoma appears to be increasing 
in people under the age of 40 years, especially among women 
(17). Furthermore, early and correct diagnosis of malignant 
melanoma is important, as it enables treatment by surgical 
resection, which is more likely to result in cure, whereas more 
advanced stages of the disease have a worse prognosis (17).
ARtificiAl intelligence-bAsed ApplicAtions
The available AI-based applications identified by the search can 
be divided into 2 groups: (i) applications with the potential 
to alert people, through the use of a mobile phone or smart 
device, when they may need to see a doctor (6, 7); and (ii) ap-
plications that help dermatologists to increase the accuracy of 
diagnosing malignant melanoma (5, 9–16). Most applications 
in the first group and some in the second group use AI based 
on fractal analysis and machine learning algorithms (1). These 
algorithms allow comparison of a stored photograph against 
numerous photographs of melanoma and benign lesions, or 
allow comparison of the stored photograph against numerous 
benign and melanoma lesion characteristics learned from 
analysing a very high number of photographs, in order to 
assess the likelihood of melanoma. 
Fractal analysis is based on a natural phenomenon that exhib-
its a repeating pattern at every scale. It can provide a quan-
titative measure of irregularity where regularity is expected 
(18). With regard to melanoma, this includes irregularities in 
the physical characteristics of a lesion, such as those used in 
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established algorithms, to assist in diagnosis (e.g. the “ABCs” 
of melanoma, in addition to texture, patterns, and other 
geome trical features). Fractal analysis has been used for the 
diagnosis of other cancers (e.g. mammography for breast 
cancer) (19) which has been used by health professionals, and 
not by patients for assessment of their own cancer risk, as for 
some of the applications identified in the current study (6, 7). 
Mobile phone ApplicAtions
The first group, mobile phone applications, are intended to 
provide information about melanoma or non-melanoma 
skin cancer, and guidance on whether people should consult 
a doctor for a specific lesion that they have photographed 
with their smart device. Some applications are also designed 
to monitor skin lesions and register whether changes occur 
with time (6, 7). The mobile phone and smart device apps can 
be divided into 2 groups: those that provide analysis of the 
image; and those that produce a store-and-forward image to 
be sent to a dermatologist for evaluation (7).
Mobile phone applications using image analysis
One review identified 39 mobile phone apps for melanoma, 
18 of which used some image analysis (6). A Cochrane Review 
of smartphone apps for triaging adults with skin lesions suspi-
cious for melanoma included 2 studies on image analysis (7). 
Both studies had a high risk of bias. Sensitivities in detecting 
melanoma ranged from 7% (95% confidence interval (95% 
CI) 2–16%) to 73% (95% CI 52–88%) and specificities ranged 
from 37% (95% CI 29–46%) to 94% (95% CI 87–97%). For an 
application to be safe, it must have almost 100% sensitivity in 
order not to miss any diagnoses of melanoma (i.e. no false-neg-
ative cases). Ideally, the application would also have high 
specificity (i.e. no false-positive cases), because false-positive 
cases cause unnecessary worry among patients. Applications 
with very high sensitivity but low specificity will also cause 
worry, and lead to many unnecessary referrals and surgery, 
thereby increasing the dermatologists’ workload. 
Mobile phone applications using store-and-forward of images
Mobile phone apps with store-and-forward of photographic 
images were used in 9 out of 39 mobile phone apps on melano-
ma (6). These applications forward a photograph of the lesion 
to an experienced professional, such as a dermatologist, for 
review, and then communicate a recommendation regarding 
the nature of the lesion to the user (6). This might also be 
termed a teledermatology service for patients. The Cochrane 
Review of smartphone applications for triaging adults with 
skin lesions suspicious for melanoma included a study using 
this store-and-forward application with high risk of bias (7). 
This study had a sensitivity of 98% (95% CI 90–100%) and 
specificity of 30% (95% CI 22–40%) (7). Thus, one diagnosis 
of melanoma was missed (one false-negative case). This ap-
plication had a specificity of only 39%, which would result 
in many unnecessary referrals to the dermatologist and many 
people worrying unnecessarily and undergoing unnecessary 
surgery (7).
Potential advantages in both groups of mobile phone apps are 
increased involvement of the public in detecting suspicious 
skin changes, including the chance of early detection of 
melanoma. Furthermore, increased patient engagement and 
involvement may result in better educated patients, and more 
effective and efficient consultations (1, 6, 7). Furthermore, 
both applications may allow better access to healthcare for 
people in remote areas. 
However, routine use of these mobile phone apps is not advised 
based on current evidence, despite their potential advantages 
(7). Mobile phone apps with image analysis are not sufficiently 
safe, as they miss cases of melanoma, and, even worse, they 
may give patients false reassurance that their lesion is not 
cancer, thus delaying diagnosis.
Evidence regarding mobile phone apps with store-and-forward 
options to the dermatologist is sparse, and involves only one 
study (7). This method seems to be more sensitive; although, 
due to low specificity, it might result in many false-positives, 
causing unnecessary referrals, surgeries and worries. 
Further development, evaluation and research into these appli-
cations is important before they can play a role in healthcare. 
It is important to note, however, that these apps are available 
to the public, and that patients will use them, even though 
they are not safe. 
ApplicAtions to help deRMAtologists incReAse the 
AccuRAcy of diAgnosing MAlignAnt MelAnoMA
The second group is applications that help dermatologists to 
increase the accuracy of diagnosing malignant melanoma. 
Diagnosis of malignant melanoma is very important, but 
also very difficult (8). Visual diagnosis is not easy, is highly 
observer-dependent, and may be associated with low accuracy 
when performed by young and unexperienced dermatologists. 
The accuracy of experts is between 75% and 84% (5, 8). Hence, 
other tests that may facilitate the diagnosis of melanoma in a 
specialist setting have been developed (5, 8–16, 19–23). These 
include reflectance confocal microscopy, optical coherence 
tomography, high frequency ultrasound, as well as comput-
er-assisted diagnosis or AI-based applications (8–16, 19–23). 
Histological confirmation of malignant melanoma remains 
the gold standard (8). AI-based applications may provide a 
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consistent and rather objective technique. They can assist 
dermatologists in different steps of analysis, such as detection 
of the lesion boundary, quantification of diagnostic features, 
classification into different lesions types (tumour staging) and 
visualization. Many studies have been published; a systematic 
review has identified 182 publications on the topic between 
1985 and 2011 (5, 10, 13). Two main types of computer-as-
sisted dermoscopy exist: computer-assisted dermoscopy based 
on dermoscopic images (CAD-derm) and computer-assisted 
dermoscopy based on spectroscopy (CAD-spect), which is 
predominantly multi-spectral-imaging (5, 10, 13). A Cochrane 
review on the use of computer-assisted dermoscopy included 
42 studies with a total of 15,938 lesions (10). Twenty-four 
studies applied CAD-derm and 18 studies used CAD-spect. 
The Cochrane review found that, for a group of 1,000 skin 
lesions, of which 200 (20%) are given the final diagnosis of 
melanoma, 386 people will have a CAD-derm result suggesting 
that a melanoma is present and, of these, 206 (53%) will have 
a false-positive result (10). Twenty (3%) of 614 people with a 
negative CAD-derm result have a melanoma (false-negative 
result). Dermoscopy or CAD-derm were found to be equal in 
their ability to detect or rule out melanoma (10). 
For a group of 1,000 people, of whom 200 (20%) are given the 
diagnosis of melanoma, 637 will have a positive CAD-spect 
result, suggesting that a melanoma is present. Of these 451 
(71%) will have a false-positive result. Fourteen (4%) of 363 
people with a positive CAD-spect result will have a melanoma 
(false-negative result) (10). CAD-spect detects more melano-
mas, but possibly produces more false-positive results (an 
increase in unnecessary surgery, referrals and worries). The 
review concludes that both CAD types demonstrate high sen-
sitivity, and could be used as a back-up for specialist diagnosis 
to assist in the diagnosis of melanomas. The Cochrane review 
concludes that the available data are too limited to make a 
judgement on which method of CAD to use (10).
Another review also evaluated the diagnostic accuracy of 
dermoscopy and digital dermoscopy for the diagnosis of 
melanoma (13). The authors retrieved 765 articles, and 30 
studies were included in their meta-analysis. The meta-ana-
lysis showed that sensitivity for CAD-based dermoscopy was 
slightly higher than for dermoscopy (91% vs. 88%; p = 0.076), 
while specificity for dermoscopy was significantly better 
than CAD-based dermoscopy (86% vs. 79%; p < 0.001). The 
diagnostic odds ratio for dermoscopy (51.5) and CAD-based 
dermoscopy (57.5) were not significantly different (p = 0.783). 
The author concluded that both tests are equal for diagnosis 
of melanoma (13). 
Based on the literature review, it appears that CAD-based 
dermoscopy has become a valuable diagnostic tool, although 
it needs further development and evaluation. It can currently 
be used as a supplement or back-up to regular dermoscopy. 
Further research is needed to establish the exact role of CAD-
based dermoscopy. 
conclusion
Applications of AI in the field of dermatology are increasing-
ly used, both by patients and health professionals. Mobile 
phone apps with image analysis for patients need further 
improvement before they can be considered safe, and not 
miss diagnoses of melanoma. CAD-based dermoscopy appears 
to have evolved into a valuable tool supplementing regular 
dermoscopy.
The majority of current AI applications involve melanoma, 
although more AI applications for the diagnosis of dermato-
logical diseases, including other types of skin cancer and other 
dermatological diseases, are anticipated.
Ultimately, while reflecting on the potential of AI to improve 
the accuracy and efficiency of dermatological diagnosis, we 
must always keep in mind the holistic nature of clinical der-
matology with its focus on the whole patient, and on effective, 
thorough and compassionate doctor–patient communication. 
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